Catalyst Net Receivables vs Total Current Assets Analysis
CPRX Stock | USD 15.87 0.05 0.31% |
Catalyst Pharmaceuticals financial indicator trend analysis is way more than just evaluating Catalyst Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Catalyst Pharmaceuticals is a good investment. Please check the relationship between Catalyst Pharmaceuticals Net Receivables and its Total Current Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalyst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.
Net Receivables vs Total Current Assets
Net Receivables vs Total Current Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Catalyst Pharmaceuticals Net Receivables account and Total Current Assets. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Catalyst Pharmaceuticals' Net Receivables and Total Current Assets is 0.56. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Total Current Assets in the same time period over historical financial statements of Catalyst Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Catalyst Pharmaceuticals' Net Receivables and Total Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Catalyst Pharmaceuticals are associated (or correlated) with its Total Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Assets has no effect on the direction of Net Receivables i.e., Catalyst Pharmaceuticals' Net Receivables and Total Current Assets go up and down completely randomly.
Correlation Coefficient | 0.56 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Net Receivables
Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Most indicators from Catalyst Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Catalyst Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalyst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.At this time, Catalyst Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 19.7 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.11 in 2024.
2023 | 2024 (projected) | Reconciled Depreciation | 24.4M | 25.6M | Net Interest Income | 1.8M | 1.0M |
Catalyst Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Catalyst Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Catalyst Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 112.4M | 192.4M | 237.8M | 375.6M | 471.9M | 495.5M | |
Total Stockholder Equity | 87.6M | 169.6M | 206.8M | 300.4M | 387.9M | 407.3M | |
Net Debt | (88.9M) | (130.2M) | (167.6M) | (294.5M) | (134.1M) | (127.4M) | |
Cash | 89.5M | 130.2M | 171.4M | 298.4M | 137.6M | 144.5M | |
Cash And Short Term Investments | 94.5M | 140.3M | 191.3M | 298.4M | 137.6M | 144.5M | |
Common Stock Shares Outstanding | 106.0M | 106.2M | 107.8M | 111.4M | 113.8M | 57.0M | |
Liabilities And Stockholders Equity | 112.4M | 192.4M | 237.8M | 375.6M | 471.9M | 495.5M | |
Other Stockholder Equity | 216.2M | 223.2M | 233.2M | 250.4M | 266.5M | 279.8M | |
Total Liab | 24.7M | 22.8M | 31.0M | 75.2M | 84.0M | 88.2M | |
Total Current Assets | 111.4M | 159.2M | 210.1M | 320.8M | 219.3M | 230.3M | |
Other Current Liab | 172.3K | 107.0K | 243K | 53.3M | 60.2M | 63.2M | |
Total Current Liabilities | 24.1M | 22.8M | 27.1M | 57.6M | 76.1M | 79.9M | |
Property Plant And Equipment Net | 1.0M | 129.8K | 4.0M | 3.6M | 3.7M | 3.9M | |
Retained Earnings | (128.7M) | (53.7M) | (26.3M) | 49.9M | 121.3M | 127.3M | |
Accounts Payable | 4.1M | 4.3M | 2.8M | 4.0M | 14.8M | 15.5M | |
Non Current Assets Total | 1.0M | 33.1M | 27.7M | 54.8M | 252.6M | 265.2M | |
Common Stock Total Equity | 103.4K | 103.8K | 103K | 105K | 120.8K | 66.6K | |
Property Plant And Equipment Gross | 1.0M | 129.8K | 4.0M | 3.6M | 4.4M | 4.6M | |
Accumulated Other Comprehensive Income | 9.5K | 31.3K | (148K) | 24K | 14K | 14.7K | |
Common Stock | 103.4K | 103.8K | 103K | 105K | 107K | 69.1K | |
Property Plant Equipment | 210.5K | 129.8K | 4.0M | 847K | 974.1K | 1.0M | |
Other Current Assets | 4.4M | 8.3M | 4.4M | 5.2M | 12.5M | 13.2M | |
Non Current Liabilities Total | 647.5K | 4.3M | 3.9M | 17.6M | 8.0M | 8.4M | |
Net Tangible Assets | 87.6M | 169.6M | 206.8M | 268.0M | 308.1M | 323.5M | |
Retained Earnings Total Equity | (160.6M) | (128.7M) | (26.3M) | 49.9M | 57.3M | 60.2M | |
Capital Surpluse | 211.3M | 216.2M | 233.2M | 250.4M | 288.0M | 169.1M | |
Inventory | 2.0M | 4.7M | 7.9M | 6.8M | 15.6M | 16.4M | |
Non Current Liabilities Other | 154.8K | 647.5K | 3.9M | 17.6M | 485K | 460.8K | |
Net Invested Capital | 87.6M | 169.6M | 206.8M | 300.4M | 387.9M | 201.8M | |
Net Working Capital | 87.3M | 136.5M | 183.0M | 263.2M | 143.3M | 147.7M | |
Capital Stock | 103.4K | 103.8K | 103K | 105K | 107K | 114.6K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.MSFT | Microsoft | |
GM | General Motors | |
CRM | Salesforce |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalyst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Catalyst Stock analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is Catalyst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalyst Pharmaceuticals. If investors know Catalyst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Catalyst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.27) | Earnings Share 0.56 | Revenue Per Share 3.771 | Quarterly Revenue Growth 0.154 | Return On Assets 0.0929 |
The market value of Catalyst Pharmaceuticals is measured differently than its book value, which is the value of Catalyst that is recorded on the company's balance sheet. Investors also form their own opinion of Catalyst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Catalyst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Catalyst Pharmaceuticals' market value can be influenced by many factors that don't directly affect Catalyst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Catalyst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Catalyst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Catalyst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.